期刊
CANCER MANAGEMENT AND RESEARCH
卷 10, 期 -, 页码 5979-5989出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S181742
关键词
hepatocellular carcinoma; HMGB3; diagnosis; prognosis; biomarker
类别
资金
- National Natural Science Foundation [81673241, 81702419]
- Projects of Jiangsu Medical Science [BE2016698]
- Graduate innovation [KYCX17_1934]
- Nantong HFPC of China [WQ2016083]
Purpose: High mobility group box 3 (HMGB3) is associated with hepatocytes malignant transformation by our previous work. We continued to investigate the diagnostic and prognostic values of HMGB3 for hepatocellular carcinoma (HCC). Patients and methods: Circulating HMGB3 levels were quantitatively detected in a cohort of 225 patients with chronic liver diseases by ELISA and compared with alpha-fetoprotein by the receiver operating characteristic curve. HMGB3 expression in tissues of 170 HCC was detected by tissue microarray and immuuohistochemistry. Relationship between HMGB3 level and HCC prognosis was evaluated by the Kaplan-Meier curves and Cox regression model. Results: The incidence of serum HMGB3 >2.0 ng/mL was 75.6% in HCC (96/127), 20.8% in liver cirrhosis (10/48), 16.0% in chronic hepatitis (8/50), and none in healthy controls (0/49). Significant difference (P<0.001) of circulating HMGB3 level was found between HCC and benign liver diseases. Total diagnostic sensitivity of serum HMGB3 plus alpha-fetoprotein was up to 89.0% for HCC. Higher HMGB3 expression was confirmed to be 73.5% in HCC tissues (125/170) >30.6% in their paracancerous tissues (52/170). HMGB3 expression was closely related to tumor size, TNM stage, poor survival, and high recurrence, suggesting an independent prognosis factor for HCC. Conclusion: HMGB3 with aberrant expression could be a novel diagnostic and prognostic marker for HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据